Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Private Advisor Group LLC

Private Advisor Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) by 13.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,770 shares of the company’s stock after buying an additional 1,790 shares during the period. Private Advisor Group LLC’s holdings in Teva Pharmaceutical Industries were worth $147,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Money Concepts Capital Corp acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $25,000. Quilter Plc acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $3,103,125,000. Tobam acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $25,000. Spire Wealth Management grew its stake in Teva Pharmaceutical Industries by 32.7% in the 2nd quarter. Spire Wealth Management now owns 5,584 shares of the company’s stock valued at $42,000 after buying an additional 1,375 shares during the last quarter. Finally, Natixis acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $61,000. 43.23% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $12.14 on Thursday. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $12.64. The company has a market capitalization of $13.61 billion, a price-to-earnings ratio of -25.83, a PEG ratio of 1.42 and a beta of 1.01. The company has a 50-day moving average of $10.88 and a 200-day moving average of $9.88. The company has a debt-to-equity ratio of 2.46, a quick ratio of 0.65 and a current ratio of 1.00.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 35.10%. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.73 billion. During the same period last year, the firm posted $0.56 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of several research analyst reports. HSBC initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, December 18th. They issued a “buy” rating and a $13.00 price target on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Monday. UBS Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and raised their price target for the stock from $11.00 to $13.00 in a research report on Monday, November 27th. Finally, Piper Sandler upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $8.00 to $12.00 in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.88.

Check Out Our Latest Research Report on TEVA

Insider Activity at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.62% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

See Also

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.